Maximizing biotech resources through strategic EMA orphan designation.

EMA Orphan Designation - For A Resource-Constrained Biotechnology Firm

Composite image showing gloved hands using a laptop, 2 laboratory flasks, as well as an older lady and an older man

Context

A biotechnology firm developing an immunotherapy for small-cell lung cancer contacted Lumis for support with an EMA orphan designation application. The client was a small, innovative company with very limited resources.

Lumis' solution

SME Status: Lumis successfully applied for an SME status for the client, an important consideration for orphan drug developers
Target Product Profile: Lumis worked with the client to develop a target product profile (TPP) for the client (e.g. specifying dosage, pharmacology, administration, safety). This was used to shape their development programme and help establish justifications for the orphan designation application.
Pre-submission: Lumis recommended the client seeks pre-submission advice from the EMA for their orphan designation. This was a strategic decision to help clarify uncertainties on areas such as preclinical development.
Clinical Justification: Despite satisfactory methods existing, Lumis managed to use the client’s data to convey a message of its potential significant benefit – a critical argument in this application for meeting the orphan designation criteria.

Result

Positive Decision on Time: The project ran within the timelines agreed during the kick-off meeting with the European Commission’s decision provided almost 2 months ahead of schedule.
Positive Regulator feedback: As well as the approval, we received positive feedback during the EMA’s pre-submission meeting as the application was described as “well prepared”.
SME Status – Cost Reduction: By combining orphan designation with SME status, the client can now fully waive EMA scientific advice fees (a saving of approximately €100k), amongst other regulator fee savings. Given the client’s limited resources, they can also benefit from increased regulator support, potential financial support, and administrative assistance.

Why this matters to sponsors

Lumis specialises in supporting small, limited resource biotechnology companies. Our solutions are devised to align with clients resource constraints, whilst providing additional strategic value to enhance cost savings. Our experience demonstrates our ability to compile high-quality submission documents and to work with regulators to obtain a positive outcome for clients and patients.

Do you need help with a clinical trial submission in the EU, UK, or Switzerland?

Speak to a senior regulatory expert

Name

Company

Phone

Service of interest?

Message

How did you hear about us?

Your data will be stored to provide you with information on our services and products. You may unsubscribe at any time. Please refer to our privacy policy for more information on how we store your data and how to unsubscribe.

If you are human, leave this field blank.